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Astrocyte loss induced by neuromyelitis optica (NMO)-IgG and complement-dependent 
cytotoxicity (CDC) is the hallmark of NMO pathology. The survival of astrocytes is thought 
to reflect astrocyte exposure to environmental factors in the CNS and the response 
of astrocytes to these factors. However, still unclear are how astrocytes respond to 
NMO-IgG and CDC, and what CNS environmental factors may impact the survival of 
astrocytes. In a murine model of NMO induced by intracerebral injection of NMO-IgG 
and human complement, we found dramatic upregulation of IL-15 in astrocytes. To 
study the role of astrocytic IL-15 in NMO, we generated a transgenic mouse line with 
targeted expression of IL-15 in astrocytes (IL-15tg), in which the expression of IL-15 is 
controlled by a glial fibrillary acidic protein promoter. We showed that astrocyte-targeted 
expression of IL-15 attenuates astrocyte injury and the loss of aquaporin-4 in the brain. 
Reduced blood–brain barrier leakage and immune cell infiltration are also found in the 
lesion of IL-15tg mice subjected to NMO induction. IL-15tg astrocytes are less susceptible 
to NMO-IgG-mediated CDC than their wild-type counterparts. The enhanced resistance 
of IL-15tg astrocytes to cytotoxicity and cell death involves NF-κB signaling pathway. Our 
findings suggest that IL-15 reduces astrocyte loss and NMO pathology.
Keywords: astrocytes, complement-dependent cytotoxicity, neuromyelitis optica-igg, il-15, neuromyelitis optica
inTrODUcTiOn
Neuromyelitis optica (NMO) is a severe autoimmune disease in the central nervous system that 
predominantly affects the optic nerves and spinal cord (1, 2). Binding of NMO-IgG to water chan-
nel aquaporin-4 (AQP4), primarily expressed at the end-feet of astrocytes, initiates complement-
dependent cell cytotoxicity (CDCC) on astrocytes, followed by blood–brain barrier breakdown, 
recruitment of granulocytes and macrophages and cytokine secretion, which result in secondary 
oligodendrocyte injury, demyelination, and neuronal injury (3–6). In NMO disease, death of astro-
cytes is thought to be pivotal because it initiates a cascade of inflammatory responses that further 
exacerbate CNS injury. Astrocytes could play an active role in regulating CNS inflammation and 
brain homeostasis via producing inflammatory mediators, energy and oxidative precursors, as well 
as scavenging extracellular cytotoxic substances in a variety of neurological diseases (7–9). Although 
it has long been known that astrocytes are targets of NMO-IgG and CDC, how astrocytes respond to 
NMO-IgG and CDC are still poorly understood.
The survival of astrocytes depends on their exposure and receptiveness to CNS environmental 
factors. Interleukin-15 is a proinflammatory cytokine that impacts the homeostasis and intensity 
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of immune response in autoimmune diseases. In the periphery, 
studies have demonstrated that IL-15 contributes to the immuno-
pathology of several inflammatory diseases, such as rheumatoid 
arthritis and inflammatory bowel disease (10, 11). In the CNS, 
IL-15 is minimally expressed in physiological conditions, but 
the level of IL-15 in the brain is upregulated after CNS injuries. 
Astrocytes have been found as a major source of IL-15 in the 
CNS after injuries (12–16). Previous studies suggest that IL-15 
would either aggravate or attenuate inflammation and neural 
injuries depending on timing, disease stage and types (17, 18). 
However, the role of IL-15 in NMO pathology remains unknown. 
In a murine model of NMO, we found that IL-15 is dramatically 
upregulated in astrocytes. To test the potential role of astrocytic 
IL-15 in NMO, we generated a transgenic mouse line with targeted 
expression of IL-15 in astrocytes (IL-15tg mice) and examined 
NMO pathology in these mice.
MaTerials anD MeThODs
Mice
The study was performed in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory 
Animals. All experimental procedures were approved by Animal 
Care and Use Committees of Barrow Neurological Institute (AZ, 
USA) and Tianjin Neurological Institute (Tianjin, China). IL-15tg 
mice were developed by Genetically Engineered Mouse Models 
Core at Univercity of Arizona (Tuscon, AZ, USA), the method of 
IL-15tg mice development and genotype identification was done 
as previously described (13–15). IL-15tg mice were backcrossed 
to the C57BL/6 background for at least 10 generations before 
experiments were performed. All mice were kept in specific 
pathogen-free conditions and kept at a standard 21°C with a 12 h 
light/dark cycle at the animal facility of the Barrow Neurological 
Institute or Tianjin Neurological Institute.
nMO animal Model Procedure
Weight-matched adult female mice, aged 8–12 weeks old IL-15tg 
mice and WT littermates, were used in our experiments. NMO 
mouse model is induced by intra-parenchymal injections of 
NMO-IgG [recombinant antibody (rAb-53)], AQP4-specific IgG, 
which is cloned from intrathecal plasma cells in early NMO (19) 
and human complement (HC). In brief, mice were anesthetized 
by inhaling 3.5% isoflurane and maintained by inhalation of 
1.0–2.0% isoflurane in 70% N2O and 30% O2 by a face mask, 
then mounted in a stereotactic frame. A midline scalp incision 
was made to expose bregma and lambda, a burr hole was made 
2 mm to the right of the bregma. A 26-gauge needle attached to 
10 µl gas-tight glass syringe (Hamilton) was inserted 3-mm deep 
to infuse 8 µl PBS containing 2 µg NMO-IgG (rAb-53) and 3 µl 
HC to the parenchymal tissue at a rate of 0.5 µl/min. During the 
entire procedure, rectal temperature was maintained at 37°C with 
a heating lamp.
neuroimaging
Neuromyelitis optica lesions and BBB permeability were detected 
using a 7T small animal, 30-cm horizontal-bore magnet and 
BioSpec Advance III spectrometer (Bruker, Billerica, MA, USA) 
with a 116-mm high power gradient set (600 mT/m) and a 72-mm 
whole-body mouse transmit/surface receive coil configuration. 
T2-weighted images were acquired at day 3 after NMO induc-
tion. Scan parameters and T2-weigthed acquisition were as we 
described previously (13–15, 20). Axial 2D multi slice T2-weighted 
images of brain were acquired with TR = 4,000 ms, TE = 60 ms, 
FOV = 19.2 mm × 19.2 mm, matrix 192 mm × 192 mm. In order 
to assess BBB permeability, the post-contrast T1 was obtained 
10 min after the administration of gadopentetate dimeglumine 
(Gd-DTPA) (Magnevist) with dosage of 0.2 mmol/kg bodyweight, 
as described (13–15, 21). Axial 2D multi slice T1-weighted 
images of brain were acquired with TR = 322 ms, TE = 10.5 ms, 
FOV =  28 mm ×  28 mm, matrix 256 mm ×  256 mm. During 
MRI scan, the animal’s respiration was continually monitored by 
a small animal monitoring and gating system (SA Instruments) 
via a pillow sensor positioned under the abdomen. Mice were 
placed on a heated circulating water blanket (Bruker) and the 
normal body temperature (36–37°C) was maintained. The MRI 
data were analyzed with Image J software (NIH).
cell isolation and Flow cytometry
Quantitative analysis of immune cell subsets and cell apoptosis 
were prepared from brain tissue and stained with fluorochrome-
conjugated antibodies as described (13–15, 22). At day 3 after 
NMO, we isolated single cell suspension from the brain. Briefly, 
mice were deeply anesthetized and brain was removed immedi-
ately after perfusion with PBS. For CNS immune cell infiltration, 
brain tissue was cut into small pieces and digested with 1 mg/ml 
collagenase in 10 mM Hepes/NaOH buffer at 37°C for 1 h. The 
cell pellet was re-suspended in 70% percoll, then overlaid with 
30% percoll. After centrifugation, the cell monolayer between 30 
and 70% percoll interface was harvested as mononuclear cells. 
For astrocyte and cell death analysis, we harvested the brain and 
homogenized with 70 µm nylon cell strainers in PBS, then, we 
removed the myelin using 30% percoll with the centrifuge at 700 g 
for 10 min. The cell pellet was collected for analysis of Caspase3 
and IL-15 expression.
We used flow cytometry to analyze leukocyte subsets and 
neural cell apoptosis. Single cell suspensions were stained with 
antibodies and appropriate isotype controls. All antibodies 
were purchased from BD Bioscience or eBioscience, Inc. unless 
otherwise indicated. The procedure of cell staining followed the 
manual protocol. The following antibodies were used: CD3 (145-
2C11), NK1.1 (PK136), CD8 (53-6.72), CD45 (30-F11), CD11b 
(M1/70), CD4 (GK1.4), Ly6G/C (RB6-8C5), glial fibrillary acidic 
protein (GFAP) (GA5), Caspase 3 (3G2). Flow cytometric data 
were acquired on a FACSAria flow cytometer (BD Bioscience) 
and analyzed with Flow Jo software version 7.6.1.
immunofluorescence and h&e staining
Mice were terminally anesthetized and perfused with PBS fol-
lowed by 4% PFA. Brains were removed and embedded in paraffin. 
5-µm thick coronal sections were deparaffinized and rehydrated 
in serial ethanol. For immunofluorescence staining, sections 
were permeabilized with 0.3% TritonX-100 for 15  min, then 
incubated with blocking solution consisting of 5% donkey serum, 
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followed by incubating with antibodies against GFAP (Abcam), 
AQP4 (Santa Cruz), Claudin5 (Life Tech) at 4°C overnight. After 
washing with PBS, slices were incubated with appropriate fluo-
rochrome conjugated secondary antibodies: donkey anti-rabbit 
488 (Invitrogen), donkey anti-goat 594 (Invitrogen), donkey 
anti-rabbit 546 (Invitrogen), respectively, at room temperature 
for 1  h. Finally, all slices were incubated with fluoro-shield 
mounting medium with DAPI (Abcam). Images were taken with 
a fluorescence microscope (model BX-61, Olympus). To get the 
image with the whole lesion in each slice, we took 10–15 visual 
fields in a row under a × 40 field of microscope around the lesion 
site (GFAP and AQP4 loss), then merged these images into a 
bigger one using the photoshop7.0 software. For H&E Staining, 
tissue sections were stained with hematoxylin and eosin. Images 
were taken with a microscope (model BX-61, Olympus). The data 
were quantified using ImageJ.
Primary astrocytes culture
Primary cortical astrocytes were prepared as previously described 
(13–15). Briefly, mixed cortices were removed from 1 to 3 days 
old WT and IL-15tg pups and minced with scissors in ice-cold 
HBSS (Gibco), then digested with 0.25% trypsin solution (Gibco) 
at 37°C for 30  min. The dissociated cells were rinsed and re-
suspended in high glucose DMEM and counted. Cells were plated 
in 35-mm culture dishes at a density of 2.5 × 104 cells/cm2. After 
2 days, the medium [High glucose DMEM (Gibco) + 10% heat-
inactivated FBS (Gibco) + 1% Penicillin/Streptomycin (Gibco)] 
was changed to remove cell debris. 7–8 days later, we passaged the 
first split astrocyte population at the appropriate cell concentra-
tion for the experiment. The purity of astrocytes was up to 95%.
complement–Dependent cytotoxicity 
(cDc)
Cultured astrocyte were plated onto 96-well microplates at 
20,000 cells/well and grown at 37°C/5% CO2 for 18–24 h. Cells 
were washed with PBS for three times and incubated on ice with 
50 µl of rAb-53 for 30 min in DMEM (Gibco). Thereafter, 2.5 µl 
pooled normal HC serum (Innovative Research) was added to the 
cells and cultured for additional 60 min at 37°C. Cytotoxicity was 
measured by lactate dehydrogenase (LDH) release assay using a 
commercial kit (Sigma) according to the manufacturer’s instruc-
tions (23). LDH release from cells was calculated as a percentage 
of total LDH in each sample.
Western Blot
Cells were lysed with cell lysis buffer (Cell Signaling Technology) 
containing protease inhibitor cocktail (Sigma-Aldrich) and 
phosphatase inhibitor mixture (Sigma-Aldrich) for 30  min on 
ice. The samples were centrifuged at 14,000 rpm for 15 min at 
4°C to remove cell debris. Protein concentration was determined 
using a BCA protein assay kit (Pierce). Proteins were subjected to 
SDS-PAGE gel (Bio-Rad) and transferred to a PVDF membrane 
(Millipore). The membrane was blocked with 5% non-fat milk in 
TBS solution containing 0.05% Tween-20 for 1 h at room temper-
ature. Then the membrane was incubated with antibodies against 
GAPDH (1:1,000), IκB (1:500, Cell signaling pathway), and pIκB 
(1:500, Cell signaling pathway) overnight at 4°C. After washing 
three times with TBST solution, the membrane was incubated 
with HRP-conjugated goat anti-rabbit (1:2,000; Zymed) for 1 h at 
room temperature. Immuno-reactive bands were detected using 
enhanced chemiluminescence (Thermo Scientific) and captured 
with an Odyssey Fc Imager (Li-cor biosciences Inc.). Western blot 
data were analyzed with ImageJ software.
statistics
We determined each sample size by power analysis using a 
significance level of α = 0.05 with 80% power to detect statisti-
cal differences. SAS 9.1 software (SAS Institute Inc., Cary, NC, 
USA) was used for power analysis and sample-size calculations. 
All values are expressed as mean ± SE. Statistical data analyses 
were performed using Graphpad Primes 6 software. Two-tailed 
unpaired Student’s t-test was used to analyze the statistical sig-
nificance of two groups. Where appropriate, One-way ANOVA 
were used for three or more groups. Values of p < 0.05 will be 
considered significant.
resUlTs
astrocyte-Targeted expression of il-15 is 
Upregulated in nMO Mice
Astrocytic IL-15 is inducible and has a dual role on brain injury in 
different CNS diseases (17, 18), to assess whether astrocytic IL-15 
level was increased in NMO, we compared the expression of IL-15 
in astrocytes in the brain tissue from the ipsilateral hemisphere 
to the contralateral hemisphere or sham control at day 3 after 
injection of recombinant NMO-IgG (rAb-53) and HC. Flow 
cytometry data show that the amount of IL-15 in astrocytes is 
much higher after NMO (Figures 1A,B), indicating that astro-
cytic IL-15 expression is related to NMO progression.
astrocyte-Targeted expression of il-15 
reduces lesion size in nMO Mice
To investigate the effect of astrocytic IL-15 in NMO, we adopted 
IL-15tg mice in which IL-15 expression is controlled by a GFAP 
promotor, as we previously reported (13–15). The expression 
level of IL-15 in astrocytes is prominently higher in IL-15tg mice 
as compared to WT littermates. Importantly, these transgenic 
mice develop normally without showing any abnormal behavior 
or infertility, and the current transgenic mice show normal nerve 
cell properties and immune system, no inflammatory infiltrates 
were seen in brain tissues of normal IL-15tg mice.
To further understand whether astrocyte-derived IL-15 affects 
NMO lesion severity, we induced an animal NMO model through 
intracerebral injection of HC and recombinant NMO-IgG 
(rAb-53) in IL-15tg mice and WT littermates. At day 3, 7T-MRI 
scans combined with conventional immunofluorescence staining 
for AQP4 and GFAP were used to evaluate NMO lesion size. MRI 
data show that the group of IL-15tg mice have markedly reduced 
NMO lesion size as compared to WT littermates (IL-15tg vs WT: 
2.40 ± 0.58 vs 5.23 ± 0.45 mm3) (Figures 2A,B), corresponding 
to less loss of GFAP and AQP4 immunostaining in the region 
of injection site (IL-15tg vs WT: 9.00 ±  2.1% vs 17.24 ±  1.9%) 
FigUre 2 | Reduced brain lesion severity and astrocytes loss in IL-15tg mice subjected to injection of neuromyelitis optica (NMO)-lgG (rAb-53) and human 
complement (HC). Mouse brains were injected with 2 µg rAb-53 plus 3 µl HC. At day 3 after NMO induction, visualization and quantification of NMO lesion size were 
taken with T2-weighted images obtained with a 7 T MRI scanner. Representative of sequential MRI images of NMO lesion in the brain from WT littermates and 
IL-15tg mice (a). The left schematic view of brain denotes the injection position (red dot) and the region of brain corresponding to the MRI image in the right. Red 
lines in the MRI images indicate the NMO lesion area. Quantification of NMO lesion volumes in MRI images (B), n = 12 mice/group. (c) Immunostaining of glial 
fibrillary acidic protein (GFAP) and aquaporin-4 (AQP4) in NMO lesion at day 3 after NMO induction. Image of whole lesion area (left panel) represented by loss of 
GFAP and AQP4 immunostaining. High magnification of immunostaining of GFAP and AQP4 around NMO lesion was shown in the right panel. White dashed line 
represents lesion area. Scale bar = 1mm (left panel) and 100 µm (right panel). (D) Quantification of the NMO lesion size with GFAP and AQP4 loss in the sections of 
WT and IL-15tg mice, n = 5 mice/group. Data represent the mean ± SE, *p < 0.05.
FigUre 1 | Upregulation of IL-15 in astrocytes after neuromyelitis optica (NMO) induction. Mouse brains were injected with 2 µg rAb-53 plus 3 µl human 
complement. At day 3 after NMO induction, the brain tissues were harvested for flow cytometry analysis. (a,B) The data show expression of IL-15 in astrocytes from 
the tissue of the ipsilateral and contralateral hemisphere, as well as sham control, n = 4 mice/group. Data represent the mean ± SE, *p < 0.05.
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(Figures 2C,D). A higher magnification of the lesion shows the 
characteristics of AQP4 and GFAP loss and reactive astrocytes 
existing around the lesion area (Figure 2C). These results indicate 
that astrocytic IL-15 may attenuate brain injury after NMO.
astrocyte-Targeted expression of il-15 
attenuates BBB leakage and Tight-
Junction loss in nMO Mice
Astrocytes, the target of NMO-IgG, are essential for the forma-
tion and maintenance of the BBB. The findings that astrocytic 
IL-15 attenuates astrocyte loss, prompted us to consider that BBB 
integrity may be preserved in IL-15tg mice. As we expected, BBB 
permeability is more prominent in WT mice than that in IL-15tg 
mice, as measured by T1 MRI scan (Figures 3A,B). The protein 
level of claudin 5, a tight junction protein, is also much higher 
in IL-15tg mice as compared to WT littermates (Figures 3C,D). 
These data further supported that astrocyte-specific expression of 
IL-15 could prevent BBB damage.
astrocyte-Targeted expression of il-15 
reduces Brain infiltration of immune cell 
subsets in nMO Mice
Injection of NMO-IgG and HC in mouse brain produces marked 
inflammation. Leukocyte infiltration and microglia activation 
contribute to the brain inflammation in NMO development. 
IL-15, as an inflammatory cytokine, has functions on a wide 
range of immune cells. To investigate the inflammation and 
immune response in the brain of WT and IL-15tg mice, we used 
H&E staining (Figures 4A,B) and flow cytometry to detect the 
subsets of leukocytes, as well as microglia, the gating strategy as 
in Figure 4C. We did not observe a significant difference in the 
FigUre 3 | Reduced blood–brain barrier permeability in IL-15tg mice subjected 
to neuromyelitis optica (NMO) induction. (a,B) T1-weighted MRI were 
performed to visualize and quantify Gd-DTPA leakage into the brain 
parenchyma in the indicated groups at day3 after NMO induction. White line 
indicates Gd-GTPA leakage area. (c,D) Immunostaining of tight junction 
protein, Claudin5, in ipsilateral NMO lesion area and contralateral corresponding 
normal area and the quantification of the intensity. n = 10 sections from three 
mice/group. Data represent the mean ± SE, *p < 0.05, **p < 0.01.
FigUre 4 | Astrocyte-targeted expression of IL-15 reduced CNS infiltration 
of immune cells. (a,B) H&E stains showed less cell density in neuromyelitis 
optica (NMO) lesions in IL-15tg mice as compared to WT mice at day 3 after 
NMO induction. n = 5 mice/group. (c–e) CNS-invading immune cell subsets 
and microglia cell numbers were analyzed using flow cytometry at day 3 after 
NMO induction. Gating strategy of immune cells including macrophage and 
neutrophils (CD45highCD11b+ly6G/C+), microglia (CD11b+CD45inter), CD4+ 
T cells (CD45highCD3+CD4+), CD8+ T cells (CD45high CD3+CD8+), NK cells 
(CD45highCD3-NK1,1+) (c). Cell number of microglia, CNS-invading immune 
cells (CD45high), and immune cell subsets decreased in IL-15tg mice as 
compared to WT mice after NMO induction (D,e), n = 5 mice/group. Data 
represent the mean ± SE, *p < 0.05.
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number of CD45int/CD11b+ (microglia) in the brain between WT 
and IL-15tg mice after NMO induction. In contrast, accumula-
tion of CD45high and Ly6G/C (macrophage and neutrophil), the 
prominent immune cells in lesions of patients with NMO, was 
markedly decreased in IL-15tg mice (Figure  4D). In addition, 
IL-15tg mice exhibited significantly reduced cell numbers of CD3, 
CD8, and NK cells in the brain as compared to WT littermates 
(Figure 4E). These data show that IL-15tg mice have extensively 
decreased leukocyte infiltration in the brain compared to WT 
littermates, indicating that the contribution of astrocytic IL-15 
to brain inflammation is likely dependent on BBB damage and 
astrocyte loss.
il-15 Promotes the survival of astrocytes 
From cDc-induced cell Death
CDC-mediated astrocyte injury is the key event during NMO 
development, which initiates secondary inflammation and NMO 
lesion development. Our findings that astrocytic IL-15 reduces 
astrocyte loss and BBB damage indicate that IL-15 may have 
the function of inhibiting astrocyte injury induced by CDC. To 
answer this question, we analyzed the cell apoptosis of astrocytes 
in the brain after NMO induction. We found that both the percent 
and cell number of astrocytes expressing caspase3 is significantly 
reduced in IL-15tg mice, suggesting that astrocytic IL-15 may have 
a function of resistance to CDC-mediated cell death (Figure 5A). 
While, there is no significant difference of astrocyte apoptosis in 
the contralateral hemisphere between WT and IL-15tg mice after 
NMO (data not shown). To further confirm the protective role of 
astrocytic IL-15, we incubated primary cultured astrocytes from 
the brain of WT and IL-15tg mice with 10 or 20 µg/ml NMO-IgG 
and 5% HC respectively. Cell viability was measured by LDH 
assay. The data show that cell death of astrocytes from IL-15tg 
mice were reduced as compared to that from WT littermates 
when cultured with 10 or 20 µg/ml NMO IgG (Figure 5B). These 
findings demonstrate that IL-15 might be a survival factor for 
astrocytes from CDC induced by NMO-IgG and HC.
il-15 Protects astrocytes against cDc via 
nF-κB signaling Pathway
NF-κB pathway has been reported to be responsible for nucleated 
cells resistant to CDC-dependent cytotoxicity (24). To determine 
whether NF-κB is involved in CDC resistance of astrocytic 
FigUre 5 | IL-15 protects astrocyte from CDC-mediated astrocyte injury. (a) Gating strategy of astrocytes expressing Caspase 3 and quantification of cell number 
of Caspase 3+ astrocytes in WT and IL-15tg neuromyelitis optica (NMO) mice at day 3 (n = 5 mice/group). (B) Quantification of lactate dehydrogenase (LDH) release 
in cultured astrocytes isolated from WT littermates and IL-15tg mice incubated with recombinant NMO-IgG (rAb-53) (10 or 20 µg/ml) and 5% human complement 
(HC) for 60 min, cell viability was determined by LDH assay. Data represent the mean (±SE) of three independent experiments. (c) Western blot were performed to 
test activation of NF-κB signaling pathway in astrocytes treated with 10 µg/ml rAb-53 and 5% HC for 60 min, pIκB values are relative to IκB (three independent 
experiments). (D) PS-1145, a NF-κB pathway inhibitor, could attenuate the protection of astrocytic IL-15 on CDC-mediated cell damage in vitro. Data represent the 
mean (±SE) of three independent experiments, *p < 0.05.
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IL-15, we compared the protein levels of phosphorylated IκB in 
astrocytes. The data show that the level of pIκB is much higher in 
astrocytes from IL-15tg mice than in WT littermates when incu-
bated with NMO-IgG with HC (Figure 5C), suggesting that IL-15 
or NMO-IgG binding could activate NF-κB signaling pathway. 
To further demonstrate whether NF-κB is responsible for CDC 
resistance, we treated astrocytes with PS-1145, which specifically 
blocks NF-κB activation by inhibiting phosphorylation of IκB. 
The data show that pretreatment of PS-1145 make the astrocytes 
from IL-15tg mice more sensitive to complement-dependent 
necrosis (Figure 5D). These results together suggest that NF-κB 
pathway may contribute to the protective role of astrocytic IL-15 
on CDC resistance after NMO.
DiscUssiOn
The current study provides the first evidence that astrocyte-derived 
IL-15 can protect against NMO pathology. As documented here, 
astrocytic IL-15 can be a survival factor to attenuate astrocytes 
loss induced by CDC, together with attenuated BBB injury and 
CNS inflammation. IL-15 augments the survival of astrocytes 
against CDC via NF-κB signaling. In all, our results reveal IL-15 
as a key factor to reduce astrocyte loss and CNS inflammation 
in NMO.
The finding that IL-15 is upregulated in astrocytes in NMO 
mice suggest that astrocytes can respond to NMO-IgG and CDC 
and modulate CNS inflammation. This is consistent with previ-
ous reports showing that astrocytes undergo dramatic changes 
of immune profiles including upregulation of chemokines and 
cytokines after the binding of NMO-IgG (25, 26). In particular, 
blockade of these factors could reduce cytotoxicity and preserve 
AQP4 protein level in cultured astrocytes (25). In contrast to the 
proinflammatory factors reported in this study, we found that 
astrocytic IL-15 reduces NMO severity and CNS inflammation, 
suggesting that astrocytes could play an active role in NMO 
pathology.
IL-15 is an inflammatory cytokine with a function on a wide 
range of immune cells (27, 28). Much evidence demonstrated that 
IL-15 can boost immune cells to exacerbate disease progression 
such as rheumatoid arthritis and stroke (13–15, 29). However, 
there are still documents, which demonstrated that IL-15 is ben-
eficial to experimental autoimmune encephalomyelitis (17, 18). 
In NMO mice, we found that IL-15 is dramatically upregulated 
in astrocytes. Using genetic manipulation, we demonstrated that 
astrocyte-specific expression of IL-15 could attenuate NMO 
pathology severity. These discrepancies between the roles of IL-15 
in different CNS diseases may contribute to the setting of these 
diseases and the pleiotropic function of IL-15. In the setting of 
NMO, CDC-mediated astrocytes loss plays a vital role in NMO 
progression, which, to large extent, determines the BBB integrity 
and immune cell infiltration. Less astrocytes damage in IL-15tg 
mice is likely to produce less immune cell infiltration. Additionally, 
it is noteworthy that IL-15 is also beneficial to neuron growth and 
development (30), whether IL-15 has the direct protective func-
tion on neuron survival or enhancing neurodegeneration needs 
further investigation.
The finding that IL-15 reduces NMO severity in mice and 
protects astrocytes against CDC has clinical relevance. As above 
described, CDC-induced astrocytes damage plays a key role in 
NMO pathology. As such, the use of IL-15 could be a candidate 
for further advanced studies to test its effectiveness to reduce 
NMO pathology. However, it is also noteworthy that the effect 
of exogenous IL-15 may be different from endogenous IL-15 as 
trans-presentation may be needed for the elaboration of IL-15 
efficacy. In addition, the efficacy of IL-15 may vary depending 
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on injected doses and their availability to various cell types that 
express IL-15 receptors. Future more advanced investigations are 
needed to better understand the role of IL-15 in NMO pathology. 
Although treatments targeting the CDC process have been inves-
tigated including complement inhibitor or NMO-IgG mutant 
(31, 32), no treatments are available to directly boost astrocyte 
survival and reduce CNS inflammation. Our results in this study 
suggest that IL-15 may serve as a potential therapy or at least a 
complementary approach to attenuate NMO pathology.
There are also limitations in this study. First, we induced NMO 
in mice by direct injection of NMO-lgG and HC into brain paren-
chyma, which may not fully mimic the scenario of pathological 
events in patients with NMO, such as the trigger of BBB breakdown, 
neuroinflammation, and peripheral immune response (33–35). 
Therefore, future studies are needed to verify our findings in other 
NMO animal models. Second, the beneficial role of IL-15 might 
be related to multiple cellular targets including CNS intrinsic cells 
and peripheral immune cell subsets. Because different doses of 
IL-15 may show different influences in nerve cells or immune cells, 
it is needed to define whether the protection of astrocytic IL-15 
in NMO depends on available IL-15 concentration. Third, IL-15 
receptors are widely expressed by CNS cell types such as neural 
progenitors. Therefore, the role of IL-15 in neuronal function or 
neurorepair warrant further investigations in future studies.
In conclusion, our studies provide novel insight astrocytic 
IL-15 in NMO pathology.
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